VOGXHealthcare · Biotechnology

VOGX Stock Forecast: Vogenx, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026

$20

+5.29% on the day

The 1 Wall Street analysts covering Vogenx, Inc. hold a median 12-month price target of $55 — +176.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$284.6M

Ticker Nerd rank

1/ 100

Median analyst target

$55

Analysts covering

Total return, dividends reinvested

+4.4%

−18.1%

From high

−41.6%

From low

+53.2%

$13

$34

Range since 12 Aug 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

VOGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vogenx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026

1/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Value

Accruals

Growth

Quality

Volatility

Issuance

Momentum

Size (62): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VOGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VOGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 12 Aug 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $55Median $55High $55

The green dot is the last close — the median target sits +176.1% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
2 Sept 2026	WBB Securities	Initiates	Speculative Buy	$42
1 Sept 2026	Jones Trading	Initiates	Buy	$55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

VOGX appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

VOGX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

VOGX vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VOGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Vogenx, Inc. (VOGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: —
Price / book: −104.5×
EV / EBITDA: −191.1×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 157.3%
Return on assets: −212.2%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vogenx, Inc. (VOGX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Vogenx, Inc. has a market value of $284.6M and an enterprise value of $285.3M.
Shares outstanding: 13.9M.
forward P/E: −11.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Vogenx, Inc. employs 4 people.

market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

VOGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
VOGXVogenx, Inc.	$284.6M	1
RCKTRocket Pharmaceuticals, Inc.	$279.2M	53
FULCFulcrum Therapeutics, Inc.	$286.1M	44
SABSSAB Biotherapeutics, Inc.	$291.2M	41
QTTBQ32 Bio, Inc.	$269.7M	74
IPSCCentury Therapeutics, Inc.	$269.5M	44
GLSIGreenwich LifeSciences, Inc.	$268.8M	35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vogenx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VOGX news & analysis

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia

Accesswire · 15 Oct 2026positive

Vogenx announced initiation of EMERGE (VGX-001-013), a Phase 2b trial evaluating mizagliflozin for post-bariatric hypoglycemia. The randomized, double-blind, placebo-controlled study will evaluate two doses in patients with recurrent hypoglycemia following bariatric surgery.

Why it matters — The trial advances Vogenx’s clinical evaluation of mizagliflozin for a condition for which the excerpt says there are no FDA-approved therapeutics.

Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer

Accesswire · 9 Oct 2026positive

Vogenx announced that Richard “Rich” Gorman will become Chief Commercial Officer on October 12, 2026, transitioning from the company’s Board of Directors. The company described his appointment as strengthening corporate strategy, business development and commercial readiness as it advances mizagliflozin.

Why it matters — The appointment adds a commercial leadership role as Vogenx advances mizagliflozin.

Vogenx Appoints Ken Toombs to Board of Directors

Accesswire · 22 Sept 2026positive

Vogenx, Inc. announced the appointment of Ken Toombs, former CEO of PA Consulting, to its Board of Directors as an independent director and Chair of the Audit Committee, effective September 21, 2026. The appointment brings three decades of global professional services and life sciences leadership experience and broadens independent oversight as the company scales following its August 2026 initial public offering.

Why it matters — For VOGX watchers, adding an experienced, independent director and Audit Committee Chair strengthens corporate governance and oversight during the company's post-IPO scaling phase.

Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering

PRNewsWire · 17 Aug 2026positive

JonesTrading Institutional Services announced it served as sole book-running manager for Vogenx, Inc.'s $81.3 million initial public offering on NASDAQ. The offering comprised 6,250,000 shares of Vogenx common stock at $13.00 per share, priced at the high end of the proposed range.

Why it matters — The IPO's completion and pricing at the high end of the proposed range is notable for Vogenx watchers as it marks the company's public market debut and reflects demand for its shares.

FAQ

Frequently asked questions about VOGX stock

What is the VOGX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Vogenx, Inc. have a median 12-month price target of $55, with estimates ranging from $55 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VOGX stock a buy right now?

Of the 1 analysts covering Vogenx, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vogenx, Inc. 1 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VOGX?

As at 28 Oct 2026, Vogenx, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (62 of 100).

Will VOGX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +176.1% from the last close, and Ticker Nerd's factor model ranks Vogenx, Inc. 1 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VOGX stock forecast for 2030?

No analyst covering Vogenx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VOGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $55 over the next 12 months.

What does Vogenx, Inc. do?

Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders.

What is the latest news on VOGX?

The most recent item we track (Accesswire, 15 Oct 2026): "Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia". Vogenx announced initiation of EMERGE (VGX-001-013), a Phase 2b trial evaluating mizagliflozin for post-bariatric hypoglycemia. The randomized, double-blind, placebo-controlled study will evaluate two doses in patients with recurrent hypoglycemia following bariatric surgery.

Company

About Vogenx, Inc.

Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders. Its current work centers on treatments for post-bariatric hypoglycemia and gastroparesis, with additional research in related rare metabolic conditions. The company’s lead program is mizagliflozin, an oral small-molecule SGLT1 inhibitor designed to address abnormal glucose absorption and other metabolic pathways in the gut. Vogenx also maintains a broader pipeline that includes additional drug candidates under evaluation for metabolic disease indications. The company serves the life sciences and drug development market, where it advances investigational therapies aimed at conditions with limited treatment options. Vogenx Inc. is headquartered in Raleigh, North Carolina and operates as a focused developer of novel medicines for metabolic and gastrointestinal disease areas.

CEO Mr. James Green · 4 employees · United States · https://vogenx.com